文献速递慢性肾脏病血液净化与透析

澳大利亚钙化防御登记:临床特征与结局

The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

仅22%患者钙化防御消退,50%在诊断后中位1.6年死亡,首年死亡率高。

要点

  • 钙化防御患者中糖尿病(76%)、肥胖(BMI 35±9 kg/m2)和维生素K拮抗剂使用(34%)常见。
  • 尽管多模式治疗,钙化防御消退率仅22%,诊断后中位1.6年死亡率达50%。

核心结论

  • 钙化防御消退不常见,诊断后第一年死亡率仍高。
  • 糖尿病、肥胖和维生素K拮抗剂使用是钙化防御的风险因素。

研究设计与样本

  • 前瞻性、基于互联网的临床登记,在澳大利亚7家机构开展,2014–2019年登记47例钙化防御病例。

主要发现

  • 患者平均年龄66±11岁,体重指数35±9 kg/m2,女性占51%。
  • 76%患者有糖尿病,34%诊断前使用维生素K拮抗剂,诊断时中位甲状旁腺激素32(IQR 14–50)pmol/L。
  • 最常见受累部位为下肢(63%),19%患者有多部位受累。

临床怎么用

  • 对终末期肾病患者应关注糖尿病、肥胖及维生素K拮抗剂使用等钙化防御风险因素。
  • 钙化防御患者即使接受多模式治疗,仍需警惕低消退率和高早期死亡率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Calciphylaxis is a rare disease, predominantly affecting patients with chronic kidney disease (CKD) and associated with significant morbidity and mortality due to progressive cutaneous calcification, necrotic ulceration and infection. Clinical registries have been established to better understand the risk factors, optimal treatments and disease outcomes of calciphylaxis. METHODS: We established a prospective, Internet-based clinical registry for the online notification of calciphylaxis cases in Australia. Seven institutions participated, with data recorded on patient characteristics, biochemical parameters, treatments and disease outcomes. RESULTS: Between 2014 and 2019, 47 cases of calciphylaxis were registered. The mean patient age was 66 ± 11 years and body mass index was 35 ± 9 kg/m2, with a higher proportion of females (51%). Eighty-seven percent of patients had end-stage kidney disease (ESKD), with 61% on hemodialysis or hemodiafiltration, with a median dialysis vintage of 4.8 [interquartile range (IQR) 1.7-7.4)] years. Five patients had CKD not requiring dialysis and two were kidney transplant recipients. Diabetes was present in 76% of patients and the cause of ESKD in 60%; 34% received vitamin K antagonists (VKAs) before diagnosis. The median parathyroid hormone level at diagnosis was 32 (IQR 14-50) pmol/L. The most common site of calciphylaxis was the lower limbs (63%), with 19% of patients having more than one area involved. Ten patients (22%) had a resolution of calciphylaxis and 25 died, with 50% mortality at a median of 1.6 (IQR 0.2-2.5) years from diagnosis. CONCLUSIONS: The Australian Calciphylaxis Registry highlights risk factors for calciphylaxis, including diabetes, obesity and VKA use. Resolution of calciphylaxis is uncommon despite multimodal therapy and mortality from calciphylaxis in the first year following diagnosis remains high.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ruderman I, Toussaint ND, Hawley CM, et al. The Australian Calciphylaxis Registry: reporting clinical features and outcomes of patients with calciphylaxis. Nephrol Dial Transplant. 2021. PMID: 31855262. doi:10.1093/ndt/gfz256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。